Home » Cardiovascular » COMMANDER HF Trial (2018): Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

COMMANDER HF Trial (2018): Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

COMMANDER HF trial

COMMANDER HF Trial Summary: Zannand F et al. randomized 5,022 patients with coronary artery disease and heart failure to undergo treatment with either rivaroxaban or a placebo. The primary objective of the study was to assess if rivaroxaban could reduce thrombin production and improve outcomes in patients with CAD and HF. The results showed that rivaroxaban did not affect the composite

Source: NEJM

Subscribe via email